# Treatment of Acute Ischemic Stroke With Rt-PA Combined With Edaravone Dexborneol

Study · id `cardio:ct-nct06248242` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT06248242](<https://clinicaltrials.gov/study/NCT06248242>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT06248242

Browse, organ or system: Brain  
Browse, condition area: Stroke  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 400 participants.

## Technical summary

Registry record NCT06248242. Randomized; double masking; primary purpose treatment. Start 2021-06-01 (actual); primary completion 2024-06-30 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; double masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 400 participants (planned count; ClinicalTrials.gov record NCT06248242, source copy `cardio:ctgov-nct06248242-2024-02-08`, retrieved 2026-10-26)
- Started: 2021-06-01 (actual) (ClinicalTrials.gov record NCT06248242, source copy `cardio:ctgov-nct06248242-2024-02-08`, retrieved 2026-10-26)
- Primary completion: 2024-06-30 (anticipated) (ClinicalTrials.gov record NCT06248242, source copy `cardio:ctgov-nct06248242-2024-02-08`, retrieved 2026-10-26)
- Completion: 2024-06-30 (anticipated) (ClinicalTrials.gov record NCT06248242, source copy `cardio:ctgov-nct06248242-2024-02-08`, retrieved 2026-10-26)
- Countries: China (ClinicalTrials.gov record NCT06248242, source copy `cardio:ctgov-nct06248242-2024-02-08`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "UNKNOWN" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct06248242-2024-02-08`, retrieved 2026-10-26)

## The registry's words

- Brief title: Treatment of Acute Ischemic Stroke With Rt-PA Combined With Edaravone Dexborneol
- Acronym: TASPE
- Condition: Acute Ischemic Stroke
- Intervention (Drug): Edaravone dexborneol
- Lead sponsor: The Second Hospital of Hebei Medical University
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Ischemic stroke (`cardio:ischemic-stroke`)
- Registry condition terms include this condition: Stroke (`core:stroke`)
- Registry lists this organization as the lead sponsor: The Second Hospital of Hebei Medical University (`cardio:org-the-second-hospital-of-hebei-medical-university`)

## Provenance

Content hash: c5230e3210b0c2956e8f5cadf372cab99c426032068802b701e351519a9ce083
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
